DelveInsight’s, “Trigeminal Neuralgia Pipeline Insights 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Trigeminal Neuralgia pipeline landscape. It covers the Trigeminal Neuralgia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Trigeminal Neuralgia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Trigeminal Neuralgia Treatment Landscape @ Trigeminal Neuralgia Pipeline Outlook

Key Takeaways from the Trigeminal Neuralgia Pipeline Report

• On July 7, 2025, Noema Pharma AG revealed the initiation of a study focused on assessing the safety and efficacy of basimglurant (NOE-101) in individuals diagnosed with trigeminal neuralgia (TN). Basimglurant is a strong inhibitor of the metabotropic glutamate receptor 5 (mGluR5), a receptor involved in numerous functions across both the central and peripheral nervous systems. Blocking mGluR5 has demonstrated therapeutic promise in managing pain linked to disorders such as TN. Clinical findings have already indicated that the drug maintains a favorable safety profile in adults, adolescents, and children. This new trial is set to explore whether basimglurant can effectively reduce both the severity and duration of TN-related facial pain, with outcomes measured through patient pain diaries and the Patient-reported Global Impression of Change (PGI-C) in comparison with baseline assessments.
• DelveInsight’s Trigeminal Neuralgia pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Trigeminal Neuralgia treatment.
• The leading Trigeminal Neuralgia Companies such as Biogen, Biohaven Pharmaceuticals, Noema Pharma AG, Pfizer and others.
• Promising Trigeminal Neuralgia Pipeline Therapies such as Carbon Dioxide Drug Delivery System (CDDS), Basimglurant, CNV1014802, Galcanezumab, COA566 and others.

Discover groundbreaking developments in Trigeminal Neuralgia Therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Trigeminal Neuralgia Clinical Trials Assessment

Trigeminal Neuralgia Emerging Drugs Profile

• Vixotrigine: Biogen

Vixotrigine (BIIB074) is a voltage and use-dependent sodium channel blocker. It is a centrally and peripherally acting small molecule. It is being developed by Biogen for the treatment of Trigeminal Neuralgia.

• Rimegepant: Biohaven Pharmaceuticals

Rimegepant is a Phase 2 calcitonin gene-related peptide receptor antagonists. It is being developed by Biohaven pharmaceuticals. The trail got initiated in June 2019 and is expected to get completed by October 2022 with expected 30 enrolled participants. (NCT03941834).

The Trigeminal Neuralgia Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Trigeminal Neuralgia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Trigeminal Neuralgia Treatment.
• Trigeminal Neuralgia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Trigeminal Neuralgia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Trigeminal Neuralgia market

Stay informed about the Trigeminal Neuralgia pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Trigeminal Neuralgia Unmet Needs

Trigeminal Neuralgia Companies

Biogen, Biohaven Pharmaceuticals, Noema Pharma AG, Pfizer and others.

Trigeminal Neuralgia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Trigeminal Neuralgia Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Transform your understanding of the Trigeminal Neuralgia Pipeline! See the latest progress in drug development and clinical research @ Trigeminal Neuralgia Market Drivers and Barriers, and Future Perspectives

Scope of the Trigeminal Neuralgia Pipeline Report

• Coverage- Global
• Trigeminal Neuralgia Companies- Biogen, Biohaven Pharmaceuticals, Noema Pharma AG, Pfizer and others.
• Trigeminal Neuralgia Pipeline Therapies- Carbon Dioxide Drug Delivery System (CDDS), Basimglurant, CNV1014802, Galcanezumab, COA566 and others.
• Trigeminal Neuralgia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Trigeminal Neuralgia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Rare Diseases Research–Access the Full Trigeminal Neuralgia Pipeline Analysis Today! @ Trigeminal Neuralgia Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Trigeminal Neuralgia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Trigeminal Neuralgia – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Trigeminal Neuralgia Collaboration Deals
9. Late Stage Products (Phase III)
10. Vixotrigine: Biogen
11. Mid Stage Products (Phase II)
12. Rimegepant: Biohaven Pharmaceuticals
13. Early Stage Products (Phase I)
14. GTX201: Grace Therapeutics
15. Pre-clinical and Discovery Stage Products
16. TNX-1900: Tonix Pharmaceuticals
17. Inactive Products
18. Trigeminal Neuralgia Key Companies
19. Trigeminal Neuralgia Key Products
20. Trigeminal Neuralgia- Unmet Needs
21. Trigeminal Neuralgia- Market Drivers and Barriers
22. Trigeminal Neuralgia- Future Perspectives and Conclusion
23. Trigeminal Neuralgia Analyst Views
24. Trigeminal Neuralgia Key Companies
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/trigeminal-neuralgia-pipeline-insight